[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"opioid-use-unspecified\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:opioid-use-unspecified":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,75,104,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100490149","influence-of-nociception-level-monitor-nol-guided-analgesic-delivery-on-robot-assisted-colorectal-surgery-100490149",false,"NCT05662371","Influence of Nociception Level Monitor (NOL) Guided Analgesic Delivery on Robot-assisted Colorectal Surgery","Influence of Nociception Level Monitor (NOL) Guided Analgesic Delivery on the Perioperative Course, Quality of Recovery and Hospital Stay in Robot-assisted Colorectal Surgery","Inclusion Criteria:\n\n* American Society of Anaesthesiologists score III-IV\n* Scheduled for elective major robot-assisted colorectal surgeries\n\nExclusion Criteria:\n\n* Inability to give informed consent\n* planned spinal or epidural anaesthesia\n* all forms of regional anaesthesia, including wound infiltration\n* nonelective procedures\n* pregnancy or lactation\n* atrial fibrillation","ALL","18 Years","80 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Being relatively new, the NOL monitor may offer interesting observations in perioperative nociception levels and appropriate analgesic consumption in diverse surgeries, including robot-assisted surgery. These observations may supplement the current efforts towards further advantages in rapid restitution. Therefore, the investigators planned a trial where intra-operative analgesics were guided using an NOL monitor to study if intra-operative NOL guidance influences peri-operative analgesic consumption, postoperative length of stay and quality of recovery of patients subjected for robot-assisted surgery.",[27,28],"Opioid Use, Unspecified","Pain, Postoperative",[30,31,32,33],"Nociception,","robotic surgery,","opioids,","postoperative recovery","RECRUITING","2026-05-11",{"date":37,"type":38},"2026-05-14","ACTUAL",{"date":40,"type":38},"2023-08-01",{"date":42,"type":21},"2027-03-31",{"name":44,"class":45},"University of Southern Denmark","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100497096","evaluation-of-the-stress-response-in-bariatric-surgery-with-and-without-the-use-of-opioids-100497096","NCT05752799","Evaluation of the Stress Response in Bariatric Surgery With and Without the Use of Opioids","Inclusion Criteria:\n\n* Age \\>18y and \\\u003C75y\n* morbid obesity confirmed diagnosis\n* American Society of Anesthesiologists (ASA) II-III\n* elective laparoscopic sleeve gastrectomy surgery\n* signed informed consent\n\nExclusion Criteria:\n\n* bradycardia, bundle branch block, hypotension, postural hypotension\n* obstructive sleep apnoea\n* history of depression\n* chronic corticosteroid use or intraoperative administration of more than 8mg of prednisolone or equivalent\n* refusal to participate","75 Years",{"count":55,"type":21},70,[24],"The goal of this clinical trial is to compare Opioid Free and Opioid Based Anaesthesia in patients undergoing sleeve gastrectomy. The main questions it aims to answer are:\n\n* Will the total dose of intraoperative opioid be reduced?\n* Will there be difference in pain scores between groups? Participants will be managed with the Nociceptive Level Index algorithm to guide intraoperative analgesia.\n\nThe Opioid Free Anaesthesia Group will be administered the Multimix infusion (Magnesium sulfate, dexmedetomidine, ketamine). The Opioid Based Anaesthesia Group will receive fentanyl as a bolus dose and remifentanil infusion.\n\nRescue fentanyl bolused will be injected as appropriate according to nociceptive level (NOL) values.",[27,59],"Bariatric Surgery Candidate",[61,62,63,64,65],"morbid obesity","opioid free anaesthesia","nociception level","analgesia","bariatric surgery","2026-04-25",{"date":68,"type":38},"2026-04-28",{"date":70,"type":38},"2023-01-01",{"date":72,"type":21},"2027-06-01",{"name":74,"class":45},"G.Gennimatas General Hospital",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100565227","sensory-outcomes-in-active-substance-users-100565227","NCT06639438","Sensory Outcomes in Active Substance Users","Molecular and Behavioral Characterization of Post-Operative Sensory Outcomes in Individuals With Chronic Pain or Persistent Opioid Use","Inclusion Criteria:\n\nOpioid user cohorts:\n\n* Individuals with current OUD as defined by The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)\n* Individuals requiring ≥20 mg of MME\u002Fday medication to manage a chronic pain problem.\n* Patients scheduled to undergo elective surgery\n* Able to provide informed consent\n\nControl Group Cohorts:\n\n* Individuals who are not taking high dose opioids (≤20 MME\u002Fday) nor illicit substances and have no history of opioid use disorder\n* Individuals with reported chronic pain not yet taking medication for their pain\n* Patients scheduled to undergo elective surgery\n* Able to provide informed consent\n\nExclusion Criteria:\n\nSubstance User Cohort:\n\n* Patients with contraindications for elective surgery\n* Individuals with no history of opioid use\n\nControl Group Cohort:\n\n* Individuals with a history of opioid use \\>20 MME\u002Fday or illicit substance use\n* Patients with contraindications for elective surgery.",{"count":83,"type":21},40,"OBSERVATIONAL","The incidence and severity of postoperative pain after spine surgery are notably high, often requiring intensive management and potentially affecting the patient's recovery, satisfaction, and long-term outcomes. Post-operative pain is particularly difficult to manage in patients with substance use disorder likely due to a combination of withdrawal symptoms and molecular changes in the pain matrix. Opiates are the leading cause of overdose related fatalities, and carry a significant burden of substance related morbidity and mortality. As over 80% of patients undergoing low-risk surgery receive opioid prescriptions, the investigators aim to identify unique molecular characteristics of pain within current and previous opioid users, which have been understudied in this context. This study also seeks to understand the molecular mechanisms underlying worsened postoperative pain in patients with opioid use disorder (OUD).\n\nFlow cytometry analysis of human serum will be done, which will assess circulating immune cells that can contribute to exacerbated surgery site inflammation. Spatial profiling of gene expression will be done in the dermis using Visium slide sequencing, focusing on the interplay between nerve endings, resident immune cells, and supporting dermal cells, all of which collectively contribute to the sensation pain. Both the visual pain rating scale and McGill Pain Questionnaire will be used to comprehensively quantify pain outcomes during the participant's postoperative recovery stay after surgery in an effort to better understand postoperative pain management with biomarkers of worsened postoperative pain.",[87,27],"Post Operative Pain",[89,90,91,92,93,94],"Opioid use disorder (OUD)","Gene expression","Visium slide sequencing","Inflammatory profile","Sensation pain","Flow cytometry","2026-02-06",{"date":97,"type":38},"2026-02-10",{"date":99,"type":38},"2025-02-02",{"date":101,"type":21},"2026-12",{"name":103,"class":45},"Boston Medical Center",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":113,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":116,"studyType":84,"phases":4,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":46},"100356620","opioid-use-disorder-in-pregnancy-in-long-term-maternalinfant-outcomes-100356620","NCT03923374","Opioid Use Disorder in Pregnancy in Long-Term Maternal\u002FInfant Outcomes","Effects of Opioid Use Disorder in Pregnancy in Long-Term Maternal\u002FInfant Outcomes","Mother\u002FBabyOUD","Inclusion Criteria:\n\n* Age greater 18 years\n* Currently taking Buprenorphine for Opioid Use Disorder and enrolled in a prenatal opioid maintenance program in the antenatal clinic at IU Health University Hospital.\n* Pregnant with single baby\n* Planned delivery at Methodist, University or Riley Hospital\n\nExclusion Criteria:\n\n* Serious maternal medical illness as deemed by study physician or investigator.\n* Known or suspected major fetal\u002Fneonatal congenital abnormalities.",true,"FEMALE",{"count":115,"type":21},600,"2 Years","The objective of this study is to better understand the comprehensive integration of both clinical and genetic factors that will help to identify mothers who could be at an increased risk of poor response to opioid substitution and infants at risk of significant neonatal abstinence syndrome (NAS).",[119,27,120],"Opioid-use Disorder","Buprenorphine Dependence",[122,123,124,125,126],"Pregnant with Opioid Use Disorder","Opioid Use Disorder ( OUD)","Subutex","Buprenorphine","Pregnant taking buprenorphine\u002Fsubutex","2025-12-16",{"date":129,"type":38},"2025-12-18",{"date":131,"type":38},"2018-09-15",{"date":133,"type":21},"2026-12-30",{"name":135,"class":45},"Senthil Sadhasivam",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":46},"100538478","phase-4-impact-of-administration-of-esmolol-on-nociception-level-guided-control-of-nociception-100538478","NCT06291363","Impact of Administration of Esmolol on Nociception Level-guided Control of Nociception.","Impact of Continuous Intraoperative Administration of Esmolol on Nociception Level-guided Control of Nociception. The EsmoNOL Randomized Controlled Trial","ESMONOL","Inclusion Criteria:\n\n* Fully consented, American Society of Anesthesiologists Classification Score 1-3 patients from 18yo to 65yo\n* Undergoing laparoscopic surgery associated with sub umbilical mini-laparotomy. Eligible surgeries will be hysterectomy (excluding vaginal approach) and left hemicolectomy, of duration time expected under 180 minutes, under general anesthesia\n* No allergy to one of the medications used in this study\n\nExclusion Criteria:\n\nContraindication to the use of the study drug (esmolol) is an exclusion criterion :\n\n* Hypotension\n* Sinus bradycardia\n* Sick sinus syndrome\n* Second and third degree A-V block\n* Pulmonary hypertension\n* Right ventricular failure secondary to pulmonary hypertension\n* Decompensated heart failure\n* Cardiogenic shock\n* Nontreated pheochromocytoma\n* Known hypersensitivity to esmolol or any of the inactive ingredients of the product\n* Allergy to esmolol or other beta blockers (cross-sensitivity is possible)\n* Renal dysfunction\n* Airway disease such as asthma or chronic obstructive pulmonary disease\n* Thyrotoxicosis\n* Myasthenia gravis\n* Raynaud's disease or peripheral circulatory disorder\n\nOther situations leading to exclusion :\n\n* Severe mental impairment\n* Chronic use of opioids, β-adrenergic receptors antagonists\n* High risk of conversion to laparotomy according to the surgical team (\\>25%)\n\nPatients will automatically be excluded after recruitment if they withdraw their consent, or if laparoscopy is converted to laparotomy.","65 Years",{"count":146,"type":21},64,[148],"PHASE4","This study aims to evaluate esmolol's perfusion impact during induction and maintenance of general anesthesia, using Nociception-Level-guided control of nociception, in adult patients undergoing laparoscopic and lower abdominal surgery, on intraoperative remifentanil consumption and postoperative pain in the Post-Anesthesia Care Unit.",[27,151,152],"Anesthesia","Nociceptive Pain",[154,155,156,157],"opioid sparing anesthesia","beta blockers","nociception monitoring","general anesthesia","2024-07-15",{"date":160,"type":38},"2024-07-16",{"date":162,"type":38},"2024-04-16",{"date":164,"type":21},"2025-03-04",{"name":166,"class":45},"Ciusss de L'Est de l'Île de Montréal"]